Company news

Share this article:

Par Pharmaceutical reached a settlement and license agreement with Ortho-McNeil Pharmaceutical, ending a patent suit related to the Johnson & Johnson unit's Ultracet acute pain product. Par said it will pay Ortho-McNeil a royalty on sales of its generic tramadol/acetaminophen product through Nov. 15 and will stop selling the product by that date. Par will also pay Ortho- McNeil royalties on sales from August 2006 to June 2007.

Novo Nordisk has filed legal action in the US to block the launch of Sanofi-Aventis' new Solo-Star insulin injection pen, The Financial Times reported. Novo Nordisk is seeking an injunction because it claims Sanofi's Solo-Star pen infringes on the patents on its NovoPen 4. Sanofi-Aventis' Solo-Star injection pen, which administers Lantus insulin, was recently approved by the FDA. Sanofi-Aventis launched Solo-Star in France and Germany in May and has plans to introduce it elsewhere across Europe and in the US in the months ahead.Both insulin pens will be competing in a global insulin market worth up to $8.2 billion. Sanofi-Aventis said in the Financial Times report that it disagreed with Novo Nordisk's claims and would “vigorously defend” its rights.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Massachusetts painkiller ban overruled

A District Court says Massachusetts cannot ban opioid painkiller Zohydro.

Ranbaxy extends branded Diovan's life

Ranbaxy may be on the blocks, but it has a hold on the right to produce generics of the Novartis heart medication Diovan. Only problem: it can't, and that is good news for Novartis.

FDA approves Glaxo's GLP-1

Type-2 diabetes injection Tanzeum, also known as albiglutide, scored the approval Tuesday.